The EPS projection of The Medicines Company (NASDAQ:MDCO) for period quarter completed 2016-12-31 is $-1.26.
The EPS estimates pronounced a week and 30 days ago were $-1.26 and $-1.26 correspondingly. The EPS forecasts specified 60 and 90 days before were $-1.26 and $-1.26 respectively. From a week ago, the aberration in EPS forecast is 0.13 percent.
The mean EPS prediction straightaway before the earnings release for the quarter completed 2 is $-1.26 based on 2 EPS estimations. The EPS stated on 2016-07-27 was $-0.84. The EPS surprise was $0.36, or 30 percent. The standard deviation as per known EPS estimates was $0.27.
The positive EPS revisions were 0 a week earlier and negative revisions were 0. In last 30 and 60 days, the positive EPS revisions were 0 and 0 correspondingly, while for 90 and 120 days, revisions count was 0 and 0.
The negative revisions of per-share earnings in the last 30 and 60-days were 0 and 0 in that order. however, for 90 and 120 days’ period, the count was 2 and 2 in that order.
EPS revisions upgrade and downgrade in the last 18 days were 0 and 2 correspondingly.
Quarterly Sales Estimates
The arithmetic mean of probable annual sales of The Medicines Company (NASDAQ:MDCO) is $32.933 and the median was $31.3. The estimate is stated by 3 analysts for the fiscal 2016.
The highest annual projection is $38 and lowest sales target is $29.5. This marks a standard deviation of $4.479.
Almost 3 have given revised positive sales forecast in the past week and 3 have downgraded forecasts. As per the stated estimates, the change in target from the past week is 8.332 percent.
Nearly 3 have revised sales projections in positive side over the past month and 3 have downgraded forecasts. This shows a mean estimate deviation of 8.332 percent.
Just about 3 have revised sales forecast on plus side over the quarter and 3 have downgraded forecasts. This shows mean estimate deviation of -14.125 percent.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...